|
|
Vaccine Detail
|
Autologous TriMix-DC Melanoma Vaccine |
| Vaccine Information |
- Vaccine Name: Autologous TriMix-DC Melanoma Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0004604
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- gp100 (PMEL)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- MAGEA3
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- MAGEC2
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- CD40LG
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Tyrosinase
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- TLR4
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- CD70
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A dendritic cell vaccine consisting of dendritic cells (DCs) electroporated with mRNA encoding three adjuvants, CD40 ligand (CD40L), a constitutively active TLR4, and CD70 (all together termed TriMix); coelectroporated with full-length mRNA encoding MAGE-A3, MAGE-C2, Tyrosinase and gp100; and linked to DC-LAMP, with potential immunostimulating activity. Upon vaccination, the DCs may stimulate the immune system to mount an antigen-specific cytotoxic T-lymphocyte (CTL) response against the melanoma antigens. This may decrease cellular proliferation of melanoma cells expressing these antigens. Electroporation with the adjuvants CD40L and TLR4 allows for the generation of mature and active DCs; electroporation with CD70 provides a costimulatory signal to CD27+ naive T cells thereby supporting T-cell proliferation and inhibiting T-cell apoptosis. (NCIT_C90560).
|
| Host Response |
|
|
| References |
NCIT_C90560: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90560]
|
|
